Zobrazeno 1 - 10 of 34 pro vyhledávání: '"Haoling H Weng"'
1
Akademický článek
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
Autor: Yulan Qi, Gina Patel, Joshua Henshaw, Soumi Gupta, Joy Olbertz, Kevin Larimore, Cary O. Harding, Markus Merilainen, Roberto Zori, Nicola Longo, Barbara K. Burton, Mingjin Li, Zhonghua Gu, Stephen J. Zoog, Haoling H. Weng, Becky Schweighardt
Publikováno v: Clinical and Translational Science, Vol 14, Iss 5, Pp 1894-1905 (2021)
Abstract Phenylketonuria (PKU), a deficiency in the activity of the enzyme phenylalanine hydroxylase, leads to toxic levels of phenylalanine (Phe) in the blood and brain. Pegvaliase (recombinant Anabaena variabilis phenylalanine ammonia lyase conjuga
Externí odkaz: https://doaj.org/article/6dddc3ccb3034bcbaa7d7af4647fea1b
Zobrazit plný text záznamu
2
Akademický článek
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trialsResearch in context
Autor: Soumi Gupta, Kelly Lau, Cary O. Harding, Gillian Shepherd, Ryan Boyer, John P. Atkinson, Vijaya Knight, Joy Olbertz, Kevin Larimore, Zhonghu Gu, Mingjin Li, Orli Rosen, Stephen J. Zoog, Haoling H. Weng, Becky Schweighardt
Publikováno v: EBioMedicine, Vol 37, Iss , Pp 366-373 (2018)
Background: This study assessed the immunogenicity of pegvaliase (recombinant Anabaena variabilis phenylalanine [Phe] ammonia lyase [PAL] conjugated with polyethylene glycol [PEG]) treatment in adults with phenylketonuria (PKU) and its impact on safe
Externí odkaz: https://doaj.org/article/35d18890af2c449283e0ae76ff18ae3e
Zobrazit plný text záznamu
3
Akademický článek
A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences
Autor: Sumitra Sri Bhashyam, Kevin Marsh, Adrian Quartel, Haoling H. Weng, Ari Gershman, Nicola Longo, Janet Thomas, Roberto Zori
Publikováno v: Molecular Genetics and Metabolism Reports, Vol 21, Iss , Pp - (2019)
Background: Phenylketonuria (PKU) leads to an accumulation of phenylalanine (Phe) in the blood and subsequent neurologic, cognitive, psychiatric, and behavioral dysfunction. Many patients report social isolation and decreased quality of life. Pegvali
Externí odkaz: https://doaj.org/article/3364638ce1c44fad95895db209531b89
Zobrazit plný text záznamu
4
Akademický článek
Assessing the Content Validity of the Investigator-Rated ADHD Rating Scale Version IV Instrument Inattention Subscale for Use in Adults With Phenylketonuria
Autor: Kathleen W. Wyrwich PhD, Katharine S. Gries PhD, Gemma Al-Jassar BSc, MSc, Elizabeth D. Bacci PhD, Yinpu Chen PhD, Rishabh Jain MS, Laurel Konkol MS, Markus J. Merilainen MD, Haoling H. Weng MD
Publikováno v: Journal of Inborn Errors of Metabolism and Screening, Vol 4 (2016)
Content validity of the 18-item Investigator-Rated Attention-Deficit Hyperactivity Disorder (ADHD) Rating Scale IV (I-ADHD RS-IV) with adult prompts was investigated using qualitative interviews of US clinicians who had prior experience rating adults
Externí odkaz: https://doaj.org/article/c134f193d0b44b85a17ad3f87103f55b
Zobrazit plný text záznamu
5
Akademický článek
An Adaptation of the Profile of Mood States for Use in Adults With Phenylketonuria
Autor: Elizabeth D. Bacci PhD, Kathleen W. Wyrwich PhD, Katharine S. Gries PhD, Yinpu Chen PhD, Rishabh Jain MS, Laurel Konkol MS, Markus J. Merilainen MD, Haoling H. Weng MD
Publikováno v: Journal of Inborn Errors of Metabolism and Screening, Vol 4 (2016)
Adults with phenylketonuria (PKU) experience disturbances in mood. This study used qualitative and quantitative techniques to adapt the 65-item Profile of Mood States (POMS) for the assessment of key mood domains in adults with PKU. First, cognitive
Externí odkaz: https://doaj.org/article/fca2200419a84504921199b56a707b44
Zobrazit plný text záznamu
6
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
Autor: Cary O. Harding, Stephen J. Zoog, Roberto T. Zori, Markus Merilainen, Joy Olbertz, Zhonghua Gu, Nicola Longo, Yulan Qi, Becky Schweighardt, Kevin Larimore, Joshua Henshaw, Barbara K. Burton, Soumi Gupta, Haoling H. Weng, Gina Patel, Mingjin Li
Publikováno v: Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 5, Pp 1894-1905 (2021)
Phenylketonuria (PKU), a deficiency in the activity of the enzyme phenylalanine hydroxylase, leads to toxic levels of phenylalanine (Phe) in the blood and brain. Pegvaliase (recombinant Anabaena variabilis phenylalanine ammonia lyase conjugated with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::634ab2a80e5f2913108fed592412a468
https://pubmed.ncbi.nlm.nih.gov/34057292
Zobrazit plný text záznamu
7
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
Autor: Mingjin Li, Soumi Gupta, Haoling H. Weng, Orli Rosen, Stephen J. Zoog, Vijaya Knight, John P. Atkinson, Joy Olbertz, Zhonghu Gu, Cary O. Harding, Kevin Larimore, Gillian M. Shepherd, Becky Schweighardt, Kelly Lau, Ryan Boyer
Publikováno v: EBioMedicine
Background This study assessed the immunogenicity of pegvaliase (recombinant Anabaena variabilis phenylalanine [Phe] ammonia lyase [PAL] conjugated with polyethylene glycol [PEG]) treatment in adults with phenylketonuria (PKU) and its impact on safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a1e965075c2259ec1adf899b479bdd
http://europepmc.org/articles/PMC6286649
Zobrazit plný text záznamu
8
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)
Autor: Zhonghua Gu, Hope Northrup, Kevin Larimore, Deborah A. Bilder, Joy Olbertz, Cary O. Harding, Prism investigators, Soumi Gupta, Haoling H. Weng, Jerry Vockley, Markus Merilainen, Stephen Amato, Joy Jiang, Janet A. Thomas, Roberto T. Zori, Harvey L. Levy, David Dimmock
Publikováno v: Molecular Genetics and Metabolism. 124:27-38
Background Phenylketonuria (PKU) is caused by phenylalanine hydroxylase (PAH) deficiency that results in phenylalanine (Phe) accumulation. Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44da0511607a58e18fbb768d234190f5
https://doi.org/10.1016/j.ymgme.2018.03.006
Zobrazit plný text záznamu
9
Assessing the Content Validity of the Investigator-Rated ADHD Rating Scale Version IV Instrument Inattention Subscale for Use in Adults With Phenylketonuria
Autor: Yinpu Chen, Katharine S. Gries, Markus Merilainen, Haoling H. Weng, Kathleen W. Wyrwich, Laurel Konkol, Gemma Al-Jassar, Elizabeth D. Bacci, Rishabh Jain
Publikováno v: Journal of Inborn Errors of Metabolism and Screening, Volume: 4, Article number: e160027, Published: 30 MAY 2019
Journal of Inborn Errors of Metabolism and Screening v.4 2016
Journal of Inborn Errors of Metabolism and Screening
Instituto Genética para Todos (IGPT)
instacron:IGPT
Journal of Inborn Errors of Metabolism and Screening, Vol 4 (2016)
Content validity of the 18-item Investigator-Rated Attention-Deficit Hyperactivity Disorder (ADHD) Rating Scale IV (I-ADHD RS-IV) with adult prompts was investigated using qualitative interviews of US clinicians who had prior experience rating adults
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27b1fbe1d58485f8ed352a8fec81a62
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942016000100319&lng=en&tlng=en
Zobrazit plný text záznamu
10
Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain
Autor: Lin Xie, Sherry Bullens, Haoling H. Weng, Athena Y. Creer, Ryan Murphy, Lening Zhang, Nathan T. Martin, Glenn Pacheco, Joy Olbertz, Geoffrey Y. Berguig
Publikováno v: Molecular genetics and metabolism. 128(4)
In phenylketonuria (PKU), mutations of the phenylalanine hydroxylase (PAH) gene decrease the ability of PAH to convert phenylalanine (Phe) to tyrosine (Tyr), resulting in Phe accumulation in the blood and brain and disruption of neurotransmitter (NT)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7ce979e820a3336eceac6170941e79
https://pubmed.ncbi.nlm.nih.gov/31648944
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje